Factor XII Inhibitors Market Expected To Grow At 10.8% CAGR Through 2030: What Businesses Need To Know
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Factor XII Inhibitors Market Forecast: What Value Will The Market Reach By 2030?
The factor xii inhibitors market has expanded considerably in recent years. It is anticipated to increase from $1.4 billion in 2025 to $1.55 billion in 2026, registering a compound annual growth rate (CAGR) of 11.1%. The expansion observed historically can be attributed to progress in coagulation biology research, a rise in the occurrence of thrombotic disorders, deficiencies of conventional anticoagulants, early positive outcomes in fxii inhibition clinical trials, and increased investment in niche and specialized treatments.
The market size for factor xii inhibitors is anticipated to grow significantly in the coming years. This market is forecast to reach a valuation of $2.34 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 10.8%. Key drivers for this growth during the projection period include the broader scope of late-stage clinical trials, a surging need for safer antithrombotic treatments, the increasing integration of precision medicine, enhanced regulatory backing for new anticoagulants, and the application of fxii inhibitors in inflammatory conditions. Significant trends observed within this period encompass the escalating creation of non-bleeding anticoagulant solutions, a heightened emphasis on modulating targeted coagulation pathways, expanding clinical assessments of fxii selective inhibitors, the broader adoption of rna-based and peptide therapeutic approaches, and improved utilization of precision drug design.
Get A Free Sample Report With In-Depth Market Insights:
Factor XII Inhibitors Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing occurrence of thrombotic conditions is anticipated to fuel the expansion of the factor XII inhibitors market. Thromboembolic conditions involve the development of blood clots within veins or arteries, which can obstruct blood flow and lead to severe health issues. The prevalence of these disorders is growing due to the rise in inactive lifestyles, which contribute to inadequate blood circulation and an elevated chance of clot formation. In managing thrombotic disorders, Factor XII inhibitors assist in preventing pathological clot formation by obstructing the contact activation pathway without disturbing normal blood clotting. This facilitates effective management of thrombosis with a reduced chance of hemorrhage. For instance, in January 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, approximately 900,000 people in the United States are affected by venous thromboembolism, of which an estimated 60,000-100,000 Americans die annually, while many others experience long-term complications. Consequently, the escalating incidence of thrombotic disorders is boosting the growth of the Factor XII inhibitors market.
Factor XII Inhibitors Market Breakdown By Product Type And Application
The factor xii inhibitors market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications
4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors
3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies
#Factor XII Inhibitors Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the Factor XII Inhibitors market are concentrating on developing innovative products, such as anti-FXIIa monoclonal antibodies, to enhance therapeutic precision and treatment effectiveness. These anti-FXIIa monoclonal antibodies are targeted biologics designed to inhibit activated factor XII, preventing abnormal clot formation while preserving normal hemostasis. For instance, in February 2025, CSL Behring GmbH, a Germany-based biopharmaceutical company, received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This product is a novel, human anti-activated factor XII monoclonal antibody approved for the prevention of acute attacks of hereditary angioedema (HAE). It functions by targeting activated factor XIIa, a key driver in the initiation of HAE attacks, and is administered through a convenient subcutaneous injection pen.
Factor XII Inhibitors Market Company Landscape And Competitive Strategy
Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC
View The Full Factor XII Inhibitors Market Report:
Factor XII Inhibitors Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
